WAVE Life Sciences Ltd
NASDAQ:WVE
Intrinsic Value
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. [ Read More ]
The intrinsic value of one WVE stock under the Base Case scenario is 3.27 USD. Compared to the current market price of 5.01 USD, WAVE Life Sciences Ltd is Overvalued by 35%.
Valuation Backtest
WAVE Life Sciences Ltd
Run backtest to discover the historical profit from buying and selling WVE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
WAVE Life Sciences Ltd
Current Assets | 235.4m |
Cash & Short-Term Investments | 200.4m |
Receivables | 21.1m |
Other Current Assets | 13.9m |
Non-Current Assets | 39.6m |
PP&E | 35.7m |
Other Non-Current Assets | 3.9m |
Current Liabilities | 186.4m |
Accounts Payable | 12.8m |
Accrued Liabilities | 23.5m |
Other Current Liabilities | 150.1m |
Non-Current Liabilities | 41m |
Other Non-Current Liabilities | 41m |
Earnings Waterfall
WAVE Life Sciences Ltd
Revenue
|
113.3m
USD
|
Operating Expenses
|
-181.3m
USD
|
Operating Income
|
-68m
USD
|
Other Expenses
|
10.5m
USD
|
Net Income
|
-57.5m
USD
|
Free Cash Flow Analysis
WAVE Life Sciences Ltd
WVE Profitability Score
Profitability Due Diligence
WAVE Life Sciences Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
WAVE Life Sciences Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
WVE Solvency Score
Solvency Due Diligence
WAVE Life Sciences Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
WAVE Life Sciences Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
WVE Price Targets Summary
WAVE Life Sciences Ltd
According to Wall Street analysts, the average 1-year price target for WVE is 13.26 USD with a low forecast of 5.05 USD and a high forecast of 19.95 USD.
Ownership
WVE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
WVE Price
WAVE Life Sciences Ltd
Average Annual Return | -9.34% |
Standard Deviation of Annual Returns | 74.55% |
Max Drawdown | -97% |
Market Capitalization | 597m USD |
Shares Outstanding | 122 284 000 |
Percentage of Shares Shorted | 5.31% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. The company employs 235 full-time employees The company went IPO on 2015-11-11. The firm is developing oligonucleotides, which targets ribonucleic acid (RNA) to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Using PRISM, its own discovery and drug development platform, which enables the precise design, optimization and production of stereopure oligonucleotides, it aspires to develop medicines for genetically defined diseases with a degree of unmet need. By intervening at the RNA level, it has the potential to address diseases with small molecules or biologics, while retaining the ability to titrate dose and avoid permanent off-target genetic changes and other challenges associated with DNA editing or gene therapy approaches.
Contact
IPO
Employees
Officers
The intrinsic value of one WVE stock under the Base Case scenario is 3.27 USD.
Compared to the current market price of 5.01 USD, WAVE Life Sciences Ltd is Overvalued by 35%.